DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Prospective, Randomized, Three Arms, Open Label Study Comparing the Safety and Efficacy of Two Formulations of PP110 to the Active Comparator Preparation-H® Cream in the Treatment of Bleeding Hemorrhoids Grades 2-3

Information source: Peritech Pharma Ltd.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Bleeding Hemorrhoids

Intervention: PP110 Gel (Drug); PP110 Medicated wipes (Drug); Preparation-H Cream (Drug)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Peritech Pharma Ltd.

Official(s) and/or principal investigator(s):
Ehud Klein, Prof., Principal Investigator, Affiliation: Maccabi Healthcare Services, Israel


Eligible patients with bleeding hemorrhoids of grade 2-3 are randomized to test-1 product (PP110 Gel), test-2 product (PP-110 medicated wipes) or control (Preparation-H cream). Test product usage: once daily, about 1-5 minutes prior to first bowel movement. Control product usage: according to label, 3-4 times daily application to rectal region. At the end of each day, subject fills a questionnaire regarding bleeding, pain, discharge, swelling, itching, discomfort and painkiller usage. Treatment is for two weeks, after which subjects fill a feedback questionnaire addressing treatment efficacy and subject satisfaction. Also, at the end of two weeks, subjects are examined by study physician who assesses hemorrhoid severity.

Clinical Details

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Bleeding / Spotting

Secondary outcome:






Painkillers usage


Minimum age: 18 Years. Maximum age: 70 Years. Gender(s): Both.


Inclusion Criteria: 1. Age 18-70 2. Bleeding hemorrhoids with / without pain 3. Diagnosis of internal hemorrhoids of grade 2-3, or external bleeding hemorrhoids 4. Signed Informed Consent Exclusion Criteria: 1. Known rectal sensitivity 2. Rectal infection 3. Grade IV hemorrhoids 4. Use of anti-coagulants (except Aspirin or Plavix) within 30 days prior to enrollment 5. Known inflammatory bowel disease 6. Anal fissure 7. Military personnel 8. Female patients that are pregnant, or are not using a reliable method of birth control, or are nursing 9. Patients who have been involved in another experimental trial within the past 30 days 10. Patients presently diagnosed with cancer

Locations and Contacts

Kfar Saba, Israel

Kiryat Ono, Israel

Modiin, Israel

Ramat-Gan, Israel

Tel-Aviv, Israel

Additional Information

Starting date: November 2013
Last updated: June 1, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017